![European medicines watchdog rejects new Alzheimer's drug](https://www.berlinertageblatt.de/media/shared/articles/16/b4/ef/European-medicines-watchdog-rejects-011215.jpg)
-
'Super proud' Sabalenka downs Pegula to win US Open thriller
-
In Papua New Guinea, Pope holds mass 'at the edge of the world'
-
Hewett stays positive for wheelchair tennis despite agonising defeat
-
Three things on US Open champion Aryna Sabalenka
-
Sabalenka downs Pegula to win US Open thriller
-
USA men land Paralympic basketball three-peat, Jiang takes 7th swim gold
-
USA slump to first home defeat against Canada in 67 years
-
Argentina hand Australia record 67-27 loss in Rugby Championship
-
England impress on Carsley bow, Germany, Dutch hit five
-
AFP photographer wins top prize for Gaza coverage
-
No Love for Packers for three weeks after ligament sprain: reports
-
Pedro Almodovar: chronicler of modern Spain crowned in Venice
-
Almodovar wins top Venice prize for end-of-life film
-
Trump sounds dark tone at rally, Harris 'ready' for debate
-
Wirtz and Musiala dazzle to kick-start new Germany era
-
Chinese teenager takes 7th gold of Paris Paralympics
-
England interim boss Carsley 'respects' divided opinions over anthem
-
Neuville moves to the front in the Acropolis Rally
-
Garfield, Pugh charm Toronto in new romance 'We Live in Time'
-
21 boys confirmed dead in Kenya school inferno
-
Over 100,000 protest in France against new prime minister
-
Golden 30 minutes takes China to swimming Paralympics swimming domination
-
Green leads Australia to T20 series sweep of Scotland
-
Nigeria, Cameroon win afer chaotic AFCON build-ups
-
Nicole Kidman: A-lister, cinematic chameleon, wins in Venice
-
'I had to prove myself', says Kolisi after win against All Blacks
-
Almodovar wins top prize at Venice film festival
-
Grealish savours England redemption after 'worst summer'
-
Carsley makes flying start as England interim boss in win over Ireland
-
Springboks close on Rugby Championship with storming win over All Blacks
-
Sri Lanka's De Silva and Kamindu Mendis defy England in third Test
-
Farrell's Racing lose on opening day of Top 14
-
Ireland and UK to 'reset' relations as Starmer visits Dublin
-
Dunbar takes second Vuelta stage as Roglic closes in on victory
-
Fritz eyes US Open glory to end 21 years of American hurt
-
Thousands protest in France against new prime minister
-
Death toll from Kenya school blaze rises to 21
-
Brazil's right rallies for 'freedom' after X suspended
-
Trump to hold rally in swing state, Harris preps for debate
-
Stone at the double as Sri Lanka collapse against England in third Test
-
French tennis player takes legal action over online abuse
-
Italy backs Kyiv's 'legitimate defence' as Zelensky presses allies
-
The Body Shop rescued from administration after deal
-
Martin roars to victory in San Marino sprint, extends MotoGP lead
-
Smoke and screams: The horror of Kenya's school dorm inferno
-
MotoGP leader Martin roars to victory in San Marino sprint
-
Ireland and UK to 'reset' relations as Starmer begins Dublin visit
-
Ma Lin turns brutal encounter with bear into glorious Paralympic career
-
Flintoff appointed England Lions head coach
-
Sri Lanka hit back as Pope falls during England collapse in second Test
![European medicines watchdog rejects new Alzheimer's drug](https://www.berlinertageblatt.de/media/shared/articles/16/b4/ef/European-medicines-watchdog-rejects-011215.jpg)
European medicines watchdog rejects new Alzheimer's drug
Europe's medicines watchdog on Friday rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits.
The decision by the Amsterdam-based European Medicines Agency was met with dismay, but experts said effective treatment for the degenerative mental disease affecting millions in Europe alone, was getting closer.
"The CHMP recommended not granting a marketing authorisation for Leqembi, a medicine intended for the treatment of Alzheimer's disease," the European Medicines Agency said, referring to its committee for evaluating drugs for human use.
Leqembi, which was developed by US multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab, which is used to treat adults with mild memory and cognitive problems resulting from the early stages of the common type of dementia.
But the CHMP said "the observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine."
"The most important safety concern with Leqembi is the frequent occurrence of amyloid-related imaging abnormalities (ARIA), a side effect, seen in brain imaging, that involves swelling and potential bleedings in the brain," the EMA said.
- 'Unmet need' -
Leqembi is a monoclonal antibody, a type of protein that clings to a substance in the brain and can delay worsening of the disease. It is given intravenously every two weeks.
Leqembi, together with another Alzheimer's drug called Aduhelm -- also developed by Biogen and Eisai -- received approval from the US Food and Drug Administration (FDA) early last year.
Both drugs were approved through an accelerated process by the FDA for drugs treating serious conditions where there is an unmet medical need.
But in late January this year, Biogen pulled the controversial Aduhelm from the market, saying it was focusing on Leqembi instead.
Preliminary data from a trial of Leqembi was released in September 2022 and found it slowed cognitive decline in Alzheimer's patients by 27 percent.
Around eight million people in the European Union live with dementia, with Alzheimer's disease accounting for more than half of these cases, according to the Alzheimer Europe website.
Eisai, in a statement, said it was "extremely disappointed with the CHMP's negative opinion".
"There is a significant unmet need for new innovative treatment options that target an underlying cause of disease progression," Eisai's chief clinical officer Lynn Kramer said.
Eisai said it would seek a re-examination of the EMA's opinion "to ensure this treatment is available for eligible people living with early Alzheimer's disease in the EU as soon as possible."
The EMA said Eisai presented a main study involving 1,795 people with early Alzheimer's who either received Leqembi or a placebo, measured over a span of 18 months.
Eisai said that the watchdog added that its refusal had "no consequences for patients in clinical trials with Leqembi".
Eisai may now ask for a re-examination within 15 days, the EMA said.
- 'Ramp up efforts' -
Experts voiced disappointment at the EMA's refusal, but added there were "reasons to remain hopeful".
"Lecanemab has shown that it is possible to slow down disease progression, and research does work," said Tara Spires-Jones, president of the British Neuroscience Association.
"Now we need to ramp up our efforts to discover new and safer treatments," she said in a statement, adding that "each discovery brings us closer to new and better treatments."
Bart De Strooper, a professor in Alzheimer's disease at the University College London called the EMA's decision "unfortunate yet not unexpected".
"This conservative approach means that patients and doctors eager to explore a proven effective drug are now denied access," he said in a statement.
"With no current therapies available, it's disheartening to think that if we had applied such caution in the past, particularly with cancer drugs and their severe side effects, we might still be without cancer treatments today," De Strooper said.
C.Kovalenko--BTB